Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats

Pediatric Research

Volumn 39, Issue 6, 1996, Pages 1028-1035

  Reijneveld, J C ^a   Koot, R W ^a   Bredman, J J ^a   Joles, J A ^b   Bar P R ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA SYNTHESIS; DRUG INDUCED DISEASE; ENZYME ACTIVITY; EXTENSOR DIGITORUM LONGUS MUSCLE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; GROWTH RETARDATION; HISTOLOGY; LIPOPHILICITY; MALE; MUSCLE INJURY; MYOPATHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SOLEUS MUSCLE; TISSUE SPECIFICITY;

EID: 0029982224     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-199606000-00016     Document Type: Article

References (55)

1. Brown MS, Goldstein JL 1984 How LDL receptors influence cholesterol and atherosclerosis. Sci Am 251:52-60
2. Illingworth DR, Bacon S 1987 Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. Am J Cardiol 60:33G-42G
3. Stein EA 1989 Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 9(suppl):I145-1151
4. Malini PL, Ambrosioni E, De Divitiis O, Di Somma S, Rosiello G, Trimarco B 1991 Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia. Clin Ther 13:500-510
5. Kwiterovich Jr PO 1993 Identification and treatment of heterozygous familial hypercholesterolemia in children and adolescents. Am J Cardiol 72:30D-37D
6. National Cholesterol Education Program 1992 Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89:525-584
7. Alberts AW 1988 HMG-CoA reductase inhibitors - the development. Atheroscler Rev 18:123-131
8. Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL, Willard AK 1986 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J Med Chem 28:849-852
9. Haruyama H, Kuwano H, Kinoshita T, Terahara A, Nishigaki T, Tamura C 1986 Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine. Chem Pharm Bull 34:1459-1467
10. Tsujita Y, Kuroda M, Shimada Y, Tansawa K, Aral M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S 1986 CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidermic effect on various animal species. Biochim Biophys Acta 877:50-60
11. McTavish D, Sorkin EM 1991 Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42:65-89
12. Tarantino MD, McNamara DJ, Granstrom P, Ellefson RD, Unger EC, Udall JN 1991 Lovastatin therapy for cholesterol ester storage disease in two sisters. J Pediatr 118:131-135
13. Conner JA, Coates PM, Liacouras CA, Jarvik GP 1993 Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. J Pediatr 123:177-184
14. Leone L, Ippoliti PF 1991 Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. [Letter] J Pediatr 119:1008-1009
15. Ducobu J, Brasseur D, Chaudron JM, Deslypere JP, Harvengt C, Muls E, Thomson M 1992 Simvastatin use in children. [Letter] Lancet 339:1488
16. Deslypere JP, Vermeulen A 1991 Rhabdomyolysis and simvastatin. [Letter] Ann Intern Med 114:342
17. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL 1991 Rhabdomyolysis with simvastatin use. [Letter] Nephron 57:365-366
18. Bizarro N, Bagolin E, Milani L, Cereser C, Finco B 1992 Massive rhabdomyolysis and simvastatin. Clin Chem 38:1504
19. Kogan A, Orenstein S 1990 Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 66:294-296
20. Goldman JA, Fishman AB, Lee JE, Johnson RJ 1989 The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 32:358-359
21. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlson A, Lindén T, Miettinen T, Odman B, Olofsson SO, Saarinen I, Sipinen R, Sjöström P, Kron B, Vanhanen H, Wright I 1993 Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 94:13-20
22. Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson SO, Berglund L, Lindén T, Sjöberg A, Bondjers G 1990 Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Int Med 228:241-247
23. Schalke BB, Schmidt B, Toyka K, Hartung HP 1992 Pravastatin-associated inflammatory myopathy. [Letter] N Engl J Med 327:649-650
24. Corsini A, Raiteri M, Soma MR, Gabbiani G, Paoletti R 1992 Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem 25:399-400
25. Goldstein JL, Brown MS 1990 Regulation of the mevalonate pathway. Nature 343:425-430
26. Jakóbisiak M, Bruno S, Skierski JS, Darewicz Z 1991 Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88:3628-3632
27. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF 1993 Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91:83-87
28. Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y 1994 Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 69:1015-1020
29. Kornbrust DJ, Macdonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI Alberts AW 1989 Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248:498-505
30. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, McDonald JS 1991 HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 257:1225-1235
31. Amelink GJ, Bär PR 1986 Exercise-induced muscle damage in the rat: effects of hormonal manipulation. J Neurol Sci 76:61-68
32. Rogers MA, Stull GA, Apple FS 1985 Creatine kinase isoenzyme activities in men and women following a marathon race. Med Sci Sports Exerc 17:679-682
33. Armstrong RB 1986 Muscle damage and endurance events. Sports Med 3:370-381
34. Kagen LJ, Aram S 1987 Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 30:213-217
35. Bar PR, Rodenburg JW, Koot RW, Amelink GJ 1994 Exercise-induced muscle damage: recent developments. Basic Appl Myol 4:5-16
36. Glantz SA 1987 Primer of Biostatistics. McGraw-Hill, New York
37. Yamauchi S, Linscheer WG, Beach DH 1991 Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats. Am J Physiol 23:G625-G630
38. Chao Y, Chen JS, Hunt VM, Kuron GW, Karkas JD, Liou R, Alberts AW 1991 Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur J Clin Pharmacol 40:S11-S14
39. Sérougne C, Mathé D, Férézou J, Bertin C, Riottot M, Lutton C, Jacotot B 1995 Effects of simvastatin on plasma lipoprotein concentrations and very-low-density lipoprotein secretion in the rat. J Clin Biochem Nutr 18:55-64
40. Mosley ST, Kalinowski SS, Schafer BL, Tanaka RD 1989 Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 30:1411-1420
41. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M 1990 Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045:115-120
42. Kalinowski SS, Tanaka RD, Mosley ST 1991 Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens. Exp Eye Res 53:179-186
43. Serajuddin ATM, Ranadive SA, Mahoney EM 1991 Relative lipophilicities, solubilities and structure-pharmacological considerations of HMG-CoA reductase inhibitors pravastatin, lovastatin, mevastatin and simvastatin. J Pharm Sci 80:830-834
44. Koga T, Fukuda K, Shimada Y, Fukami M, Tsujita Y 1992 Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209:315-319
45. De Vries ACJ, Vermeer MA, Bredman JJ, Bär PR, Cohen LH 1992 Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin. Exp Eye Res 56:393-399
46. Fridén J, Sjöström M, Ekblom B 1981 A morphological study of delayed muscle soreness. Experientia 37:506-507
47. London SF, Gross KF, Ringel SP 1991 Cholesterol-lowering agent myopathy (CLAM). Neurology 41:1159-1160
48. Mokri B, Engel AG 1975 Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology 25:1111-1120
49. Schmalbruch H 1975 Segmental fibre breakdown and defects of the plasmalemma in diseased human muscles. Acta Neuropathol 33:129-141
50. Soza M, Karpati G, Carpenter S, Prescott S 1986 Calcium-induced damage of skeletal muscle fibers is markedly reduced by calcium channel blockers. Acta Neuropathol 71:70-75
51. Baracos V, Greenberg RE, Goldberg AL 1986 Influence of calcium and other divalent cations on protein turnover in rat skeletal muscle. Am J Physiol 250:E702-E710
52. 2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 202:1579-1585
53. 2+-dependent potassium channels. Biomed Biochim Acta 48:3825-3875
54. Fairbanks KP, Witte LD, Goodman DS 1984 Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 259:1546-1551
55. Knipscheer HC, Boelen CCA, Kastelein JJP, van Diermen DE, Groenemeijer BE, Van den Ende A, Büller HR, Bakker HD 1996 Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39:867-871